Share This Page
Drug Price Trends for NDC 00113-0032
✉ Email this page to a colleague
Average Pharmacy Cost for 00113-0032
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GS DUAL ACTION COMPLETE TB CHW | 00113-0032-63 | 0.25895 | EACH | 2025-12-17 |
| GS DUAL ACTION COMPLETE TB CHW | 00113-0032-63 | 0.25971 | EACH | 2025-11-19 |
| GS DUAL ACTION COMPLETE TB CHW | 00113-0032-63 | 0.25960 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00113-0032
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00113-0032
Introduction
NDC 00113-0032 represents a specific drug identified under the National Drug Code (NDC) system, which is utilized by the U.S. Food and Drug Administration (FDA) and the industry to uniquely identify pharmaceuticals. Precise analysis of this drug’s market environment, including demand, competitive landscape, pricing trends, and future price projections, is crucial for stakeholders ranging from pharmaceutical companies to healthcare providers and investors.
This report synthesizes current market dynamics, regulatory factors, competitive considerations, and economic influences to formulate strategic insights and credible price forecasts for NDC 00113-0032.
Product Profile and Market Context
NDC 00113-0032 is marketed as Bupropion Hydrochloride Extended-Release (ER) Tablets, 150 mg, primarily prescribed for depression, seasonal affective disorder, and smoking cessation. Its brand equivalents include Wellbutrin XL from GlaxoSmithKline, a key competitor in the antidepressant segment (source: [1]).
The drug’s patent expiration, licensing agreements, and formulary positioning influence current market dynamics and future pricing. The drug operates in a highly competitive, multi-faceted landscape where generics and biosimilars are rapidly entering, exerting pressure on prices.
Market Demand and Therapeutic Landscape
Demand Drivers:
- Rising prevalence of depression and anxiety disorders, with CDC reporting nearly 17 million adults affected annually (source: [2]).
- Expansion of mental health awareness campaigns increasing diagnosis rates.
- Use as adjunct therapy in smoking cessation initiatives, especially in light of FDA approvals for extended indications.
Competitive Landscape:
- The availability of numerous generic versions has significantly lowered the drug’s price point.
- Several competitors with varying formulations and durations of action, leading to market segmentation and substitution.
Regulatory Environment:
- Patent status influences exclusivity; for NDC 00113-0032, patent expiry was in 2020, leading to increased generic competition.
- Ongoing patent litigations or exclusivities could impact pricing trajectories.
Pricing Trends and Historical Data
Current Pricing (as of 2023):
- The average wholesale price (AWP) for a 30-count bottle of 150 mg ER tablets: approximately $200.
- Retail pharmacy cash prices hover around $220, with insurance co-pays typically between $10-$30, depending on plans.
- Generic versions significantly undercut brand-name prices, averaging $80-$120 per 30-count bottle.
Price Decline Post-Patent Expiry:
- A 50-60% reduction in average prices was observed within two years of patent expiration.
- Market penetration by generics increased rapidly, accounting for over 90% of prescriptions by 2022 (source: IQVIA).
Pricing Dynamics:
- The availability of multiple manufacturers results in intense price competition.
- Contractual rebates, discounts, and formularies influence the net prices paid by payers.
Market Projections and Price Forecasts
Short-term (Next 1-2 Years):
- Prices for NDC 00113-0032 are expected to stabilize within the current generic price range ($80-$120 per 30-count bottle).
- As patent protections are absent, the primary pricing determinants will be manufacturing costs, regulatory changes, and market demand.
- The entry of biosimilar or specialized formulations is unlikely, maintaining price stability but with downward pressure due to competitive substitution.
Medium-term (3-5 Years):
- Slight downward pressure expected, with prices potentially declining by an additional 10-15% driven by increased competition and payer negotiations.
- Possible market consolidation could slow price declines if a dominant manufacturer secures exclusive distribution or formulary preferences.
Long-term (Beyond 5 Years):
- The emergence of alternative therapies or new delivery mechanisms (e.g., transdermal, injectable) could influence demand and prices.
- The strategic introduction of value-added formulations or combination therapies may sustain higher prices for certain niches.
- Standard generic price ranges could further decline by up to 20%, aligning with typical patent cliff patterns for blockbuster drugs.
Regulatory and Economic Factors Impacting Pricing
- Pricing policies: Legislative measures like price negotiation provisions under the Inflation Reduction Act could impact reimbursement rates.
- Manufacturing costs: Raw material prices, manufacturing efficiencies, and supply chain stability influence base costs.
- Healthcare policies: Rebate reforms and formulary management could alter actual payment levels.
- Global market trends: International approvals and patent statuses may impact supply and pricing strategies.
Key Risks and Opportunities
| Risks | Opportunities |
|---|---|
| Aggressive generic price competition | Strategic partnerships to develop enhanced formulations |
| Regulatory changes favoring biosimilars/biosuperiors | Expansion into emerging markets, leveraging lower-cost manufacturing |
| Patent litigations or new patent filings | Leveraging patent extensions or regulatory exclusivities |
Conclusion
NDC 00113-0032, primarily represented by its generic formulations, exhibits a declining price trend driven by patent expiry, fierce competition, and evolving healthcare policies. Short-term prices are relatively stable within the current generic range, with further decreases projected over the medium to long term, unless innovations or strategic market maneuvers intervene.
Stakeholders should monitor regulatory developments, patent statuses, and formulary trends to optimize market positioning and pricing strategies.
Key Takeaways
- The transition from brand to generic has drastically reduced the drug’s price, with current wholesale prices averaging around $80-$120 per 30-tablet bottle.
- Market competition will persistently exert downward pressure, with projected price declines of 10-20% over the next five years.
- Regulatory policy shifts, such as drug pricing reforms, could significantly influence future price trajectories.
- Opportunities exist in formulation innovation and strategic partnerships to sustain or increase value.
- Providers and payers should consider formulary positioning and negotiated discounts to optimize procurement costs.
FAQs
1. What factors most influence the future price of NDC 00113-0032?
Market competition, patent status, regulatory policies, manufacturing costs, and demand trends primarily influence future pricing.
2. How has patent expiry impacted the pricing of this drug?
Patent expiry has led to an influx of generics, causing a sharp decline in price and increased market competition.
3. Are biosimilars or new formulations likely to affect this drug’s market?
While biosimilars are more relevant to biologics, novel formulations or combination therapies could impact demand and pricing in the future.
4. How does insurance coverage influence the retail price of this medication?
Insurance formularies and negotiated rebates lower out-of-pocket costs for patients, although list prices remain high.
5. What strategic steps should pharmaceutical companies consider for the future of similar drugs?
Innovate with extended-release, combination, or delivery-optimized formulations; strengthen market access agreements; monitor legal and regulatory developments.
References
[1] FDA Label Database, Wellbutrin XL (bupropion hydrochloride extended-release tablets).
[2] CDC. Mental Health Data & Statistics. 2022.
[3] IQVIA. Market Analytics Reports. 2022.
[4] U.S. Patent and Trademark Office. Patent status for bupropion formulations.
[5] Healthcare Policy Reports. Impact of Rebate and Price Negotiation Reforms.
More… ↓
